Compare First Trust NASDAQ Clean Edge Green Energy Idx Fd (QCLN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust NASDAQ Clean Edge Green Energy Idx Fd vs State Street SPDR S&P Biotech ETF — how do they compare? First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $53.03, while State Street SPDR S&P Biotech ETF trades at $152.12. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals.
| QCLN | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $68.47 | $164.28 |
52-Week Low | $34.31 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QCLN trades at $51.25, down 1.9% with a bearish technical signal showing 17 sell indicators versus 3 buy signals. The ETF faces headwinds from regulatory uncertainty around renewable energy permits and supply chain pressures, though long-term growth prospects remain supported by rising data center energy demand and global clean energy investments. Technical analysis indicates strong resistance at $52-$56 with support at $48-$51.
The clean energy sector faces near-term policy risks but benefits from structural tailwinds. Investment appeal depends on resolution of US permit delays and China trade tensions, with current technical weakness suggesting cautious entry points may emerge near support levels for long-term positioning in the energy transition theme.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Trust NASDAQ Clean Edge Green Energy Idx Fd
QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
